



## Article

# Prognostic Factors for Immune Thrombocytopenic Purpura Remission after Laparoscopic Splenectomy: A Cohort Study

Anna Kwiatkowska <sup>1</sup>, Dorota Radkowiak <sup>1</sup>, Michał Wysocki <sup>1,2</sup>, Grzegorz Torbicz <sup>1</sup>,  
Natalia Gajewska <sup>1</sup>, Anna Lasek <sup>1</sup>, Jan Kulawik <sup>1</sup>, Andrzej Budzyński <sup>1,2</sup>  and  
Michał Pędziwiatr <sup>1,2,\*</sup> 

<sup>1</sup> 2nd Department of General Surgery, Jagiellonian University Medical College, Kopernika 21, 31-501 Kraków, Poland; anna.zychowicz@onet.pl (A.K.); dradkowiak@gmail.com (D.R.); m.wysocki@doctoral.uj.edu.pl (M.W.); grzegorz.torbicz@gmail.com (G.T.); natgajewska@gmail.com (N.G.); aniad303@gmail.com (A.L.); jankula@poczta.onet.pl (J.K.); andrzej.budzynski@uj.edu.pl (A.B.)

<sup>2</sup> Centre for Research, Training and Innovation in Surgery (CERTAIN Surgery), 31-501 Kraków, Poland

\* Correspondence: michal.pedziwiatr@uj.edu.pl; Tel.: +48-608-552-323; Fax: +48-124-213-456

Received: 5 March 2019; Accepted: 11 April 2019; Published: 18 April 2019



**Abstract:** *Background and Objectives:* Laparoscopic splenectomy (LS) has become the gold standard for patients with immune thrombocytopenic purpura (ITP). The total remission rate after splenectomy is 70%–90%, of which 66% is long-term. Despite this high response rate, some patients do not benefit from surgery. It is therefore important to try to identify risk factors for an unsatisfactory clinical response. The aim of this study was to assess long-term outcomes of LS for ITP and identify factors associated with increased disease remission rates. *Materials and Methods:* We retrospectively studied consecutive patients with ITP undergoing LS in a tertiary referral surgical center prospectively recorded in a database. Inclusion criteria were: Elective, laparoscopic splenectomy for diagnosed ITP, and complete follow-up. The cohort was divided into two groups—Group 1 (G1) patients with ITP remission after splenectomy and Group 2 (G2) patients without remission. There were 113 G1 patients and 52 G2 patients. Median follow-up was 9.5 (IQR: 5–15) years. *Results:* In univariate analysis, patient's age, body mass index (BMI), preoperative platelet count, the need for platelet transfusions, and presence of hemorrhagic diathesis were shown to be statistically significant factors. Next, we built a multivariate logistic regression model using factors significant in univariate analysis. Age <41 years (odds ratio (OR) 4.49; 95% CI: 1.66–12.09), BMI < 24.3 kg/m<sup>2</sup> (OR: 4.67; 95% CI: 1.44–15.16), and preoperative platelet count  $\geq 97 \times 10^3/\text{mm}^3$  (OR: 3.50; 95% CI: 1.30–9.47) were shown to be independent prognostic factors for ITP remission after LS. *Conclusions:* The independent prognostic factors for ITP remission after LS revealed in our study are: age <41 years, BMI < 24.3 kg/m<sup>2</sup>, and preoperative platelet count  $\geq 97 \times 10^3/\text{mm}^3$ . Duration of the ITP and the time of treatment are not related to remission after LS.

**Keywords:** splenectomy; ITP; immune thrombocytopenia; laparoscopy; remission; long-term outcomes

## 1. Introduction

Immune thrombocytopenic purpura (ITP) is a hematological disorder characterized by autoimmune-mediated destruction of platelets and reduction of platelet production. In general, the mainstays of medical therapy are corticosteroids and intravenous immunoglobulins. However, long-term remission rates are only 20% to 25% in adults [1,2]. Splenectomy is a main second-line treatment in refractory ITP [3,4]. Since the very first laparoscopic splenectomy was carried out

by Delaitre and Maignien in 1991, it has become the gold standard for patients with ITP [5]. The total remission rate after splenectomy is 70%–90%, 66% of whom have long-term remission without additional therapy [6]. Although the choice of surgical approach (laparoscopic) in case of splenectomy is straightforward due to the obvious benefits of minimally invasive surgery, the decision about splenectomy timing itself is still difficult [7–9]. The reason is that despite the high response rate of splenectomy, some patients do not benefit from surgery. For this reason, it seems reasonable to identify risk factors for satisfactory clinical response and failure in patients operated on for ITP. The aim of the study was to assess long-term outcomes of laparoscopic splenectomy (LS) for ITP and identify factors associated with increased remission rates.

## 2. Materials and Methods

### 2.1. Design

This was a retrospective cohort study of consecutive patients with ITP undergoing LS between 1998 and 2017 in a tertiary referral, university-affiliated, surgical center, that were prospectively recorded in a database. Inclusion criteria were: Elective, laparoscopic splenectomy for diagnosed ITP, and complete follow-up. Patients with unclear diagnosis of ITP, splenic trauma, initially submitted to open surgery, partial resections and other spleen-preserving procedures were excluded from further analyses. The entire cohort was divided into two groups—Group 1 patients with ITP remission after splenectomy and Group 2 patients without remission. All patients were followed up strictly for the first postoperative month. To collect long-term data, we contacted the patients and checked their remission status. The minimal time interval between surgery and follow-up was one year after surgery.

### 2.2. Definitions

Symptomatic ITP is defined as thrombocytopenia associated with petechiae or purpura, unusual/non-occasional hematomas, persistent bleeding from wounds or other injuries, mucosal bleeding, frequent or heavy epistaxis, and/or hemorrhage from any site (usually gingival or menorrhagia in women).

Remission (response) was defined as a platelet count of  $>100 \times 10^3/\text{mm}^3$  in follow-up, no symptoms of ITP and bleedings at the time of follow-up, and no current or postoperative treatment of ITP. Non-remission (non-response) was defined as a lack of a rise in platelet count to  $100 \times 10^3/\text{mm}^3$  or an initial rise but return to values  $<100 \times 10^3/\text{mm}^3$  postoperatively. The need to restart or continue steroids or other therapy to sustain normal platelet count or spontaneous bleeding within 30 days after splenectomy was also considered non-remission (non-response). Additionally, we performed analyses for durable postoperative platelet count of  $>50 \times 10^3/\text{mm}^3$  in follow-up.

All patients were preoperatively assessed by a hematologist and appropriate treatment introduced according to our predefined protocol [10]. Operative time measurement was measured from skin incision to closure. The intraoperative blood loss was the amount of blood aspirated by the suction machine. Intraoperative adverse events were defined as any iatrogenic harmful event occurring during the operation not derived from the standard course of operation. Intraoperative blood loss  $\geq 500$  mL was considered to be hemorrhage, because losing less than one unit of blood (500 mL) usually does not negatively affect the condition of the patient and does not lead to hypovolemia and hemorrhagic shock [11,12]. Perioperative morbidity was defined as any complication or deviation from a routine postoperative course observed during 30 days after LS (graded with Clavien–Dindo classification [13]). Postoperatively, patients were followed-up by a hematologist or family doctor.

### 2.3. Operative Technique

The primary choice in all cases was four-port laparoscopic splenectomy. In the beginning of our experience in LS, we predominantly used the “vessels first” technique, as described elsewhere [14,15].



Later, the “hilar transection” technique was used, as we have described previously [16]. Occasionally, the operator placed clips on larger vessel branches of the hilum to ensure proper hemostasis.

#### 2.4. Ethics

This study meets the Report of the ISPOR Task Force on Retrospective Databases guidelines [17]. All procedures followed the ethical standards on human experimentation, both institutional and national, including the Fortaleza revision of the 1975 Declaration of Helsinki. The study was approved by the Bioethical Committee of the Jagiellonian University, Krakow, Poland (approval number 1072/6120/160/2017 from 21 December 2017). Informed consent for the surgical treatment was obtained from all patients before the procedure.

#### 2.5. Statistical Analysis

Data analyses were performed using Statsoft STATISTICA v.13.5 software (Statsoft Inc., Tulsa, OK, USA). Continuous variables are presented as mean  $\pm$  standard deviation (SD) or median and interquartile range (IQR), when appropriate. Categorical variables were analyzed in Pearson's chi-square test or chi-square with Yates correction, when appropriate. The Shapiro–Wilk test was used to analyze if continuous variables were normally distributed. Continuous data was analyzed with the Student's *t*-test (for normally distributed) and the Mann–Whitney U test (for non-normally distributed data). Finally, univariate and then multivariate logistic regression analyses were built in search of factors influencing odds ratios (OR) with 95% confidence interval (95% CI) of primary and secondary outcomes. Receiver operating characteristic (ROC) curves were used to set cut-off points in the process of conversion from a continuous to a dichotomous variable. A Kaplan–Meier curve was built for remission status within the study period. Results were considered statistically significant when the *p*-value was less than 0.05.

### 3. Results

#### Patients

A total of 165 patients with ITP fulfilling inclusion criteria were treated in our department between 1998 and 2017. Study groups consisted of 113 patients with ITP remission (Group 1) and 52 without remission (Group 2). Baseline characteristics of the study cohort are presented in Table 1. Median follow-up was 9.5 (IQR: 5–15) years. There were no differences in gender between the groups. Patients in group 1 were significantly younger ( $p < 0.001$ ), had a lower BMI ( $p = 0.002$ ), and had a higher preoperative platelet amount ( $p = 0.034$ ).

Complications occurred in 13 patients (7.88%), with nine (7.96%) of them in Group 1 and four (7.69%) in Group 2 (Table 2). There were no conversions. One patient died after surgery due to a pulmonary embolism, hence they were not observed long-term. The median hospital stay was four days (IQR 3–4), three days for Group 1 (IQR 3–4), and four days for Group 2 (IQR 3–5).

**Table 1.** Patients' characteristics.


|   | All <i>n</i> = 165 (100%) | Group 1 <i>n</i> = 113 (68.48%) | Group 2 <i>n</i> = 52 (31.52%) | <i>p</i> -Value |
|---|---------------------------|---------------------------------|--------------------------------|-----------------|
| Gender, <i>n</i> (%) male female  | 52 (32) 113 (68)          | 34 (30) 79 (70)                 | 18 (35) 34 (65)                | 0.561           |
| Age, median (IQR), years  | 35 (25–52)                | 31 (24–48)                      | 50 (36.5–60)                   | <0.001          |
| BMI, median (IQR), kg/m <sup>2</sup>  | 25.69 (21.76–29.30)       | 24.30 (20.52–29.01)             | 27.65 (25.50–30.62)            | <0.001          |
| Spleen size, median (IQR), cm   | 11 (10–12)                | 11 (10–12)                      | 11 (10–12)                     | 0.599           |
| Lowest preoperative platelet count, median (IQR), ×10 <sup>3</sup> /mm <sup>3</sup> | 8 (4–16)                  | 10 (5–18)                       | 7 (3–12)                       | 0.071           |
| Preoperative platelet count, median (IQR), ×10 <sup>3</sup> /mm <sup>3</sup>        | 90 (48–119)               | 97 (50–125)                     | 68.5 (36.5–107)                | 0.034           |
| Preoperative steroids administration, <i>n</i> (%)                                  | 158 (95.76)               | 107 (94.69)                     | 51 (98.08)                     | 0.293           |
| Immunoglobulin administration, <i>n</i> (%)   | 37 (22.42)                | 26 (23.01)                      | 11 (21.15)                     | 0.791           |
| Preoperative platelet transfusions, <i>n</i> (%)                                    | 19 (11.52)                | 9 (7.96)                        | 10 (19.23)                     | 0.065           |
| Accessory spleen, <i>n</i> (%)  | 36 (21.82)                | 25 (22.12)                      | 11 (21.15)                     | 0.950           |
| Perioperative complications, <i>n</i> (%)   | 13 (7.88)                 | 9 (7.96)                        | 4 (7.69)                       | 0.610           |
| Blood transfusions, <i>n</i> (%)  | 3 (1.82)                  | 1 (0.88)                        | 2 (2.85)                       | 0.234           |
| Time from diagnosis of ITP to procedures, median (IQR), months                      | 24 (6.75–57)              | 18 (6.5–48)                     | 24 (9–84)                      | 0.241           |
| Symptomatic ITP, <i>n</i> (%)   | 90 (54.55)                | 59 (52.21)                      | 31 (59.62)                     | 0.375           |
| Preoperative time of conservative treatment, median (IQR), months                   | 9.5 (5–30)                | 8.5 (4.5–24)                    | 12 (5–51)                      | 0.178           |

**Table 2.** Perioperative morbidity.

|                                       | All  | Group 1     | Group 2       |
|---------------------------------------|--|-------------|---------------|
| Operative time, median (IQR), min     | 85 (65–105)                                | 80 (60–100) | 90 (70–110)   |
| Blood loss, median (IQR), mL          | 50 (20–100)                                | 30 (10–50)  | 50 (20–100)   |
| LOS, median (IQR), days               | 4 (3–4)                                    | 3 (3–4)     | 4 (3–5)       |
| Perioperative morbidity, <i>n</i> (%) | 13 (7.88)                                  | 9 (7.96)    | 4 (7.69)      |
| Clavien–Dindo                         | Morbidity                                  | Remission   | Non-remission |
| IIIb                                  | Acute pancreatitis, sub-phrenic abscess    | 1           | 0             |
|                                       | Gastric perforation, sub-phrenic abscesses | 1           | 0             |
|                                       | Peritonitis, intra-abdominal abscesses     | 1           | 0             |
|                                       | Intra-abdominal bleeding                   | 5           | 3             |
| IIIa                                  | Pancreatitis                               | 1           | 1             |
| II                                    | Pneumonia                                  | 2           | 0             |
|                                       | Postoperative fever                        | 1           | 0             |
| I                                     | Sub-phrenic fluid collection               | 1           | 0             |

The Kaplan–Meier curve demonstrating probability of full remission against time of observation is presented in Figure ??.

Univariate logistic regression identified factors that may impact remission after LS (Table 3). In univariate analysis, age, BMI, preoperative platelet count, and the need for platelet transfusions were found to be statistically significant. Next, we built multivariate logistic regression model using items significant in univariate analysis (Table 4). Continuous variables used in univariate logistic regression models were dichotomized using ROC analyses. Cut-off points are shown in Table 4. Area under curve (AUC) for age was 0.72 (95% CI 0.63–0.81, *p* < 0.001), for BMI 0.71 (95% CI 0.62–0.80, *p* < 0.001), and for preoperative platelet count 0.61 (95% CI 0.51–0.70, *p* = 0.030). Age <41 years, BMI < 24.3 kg/m<sup>2</sup>, and preoperative platelet count ≥97 × 10<sup>3</sup>/mm<sup>3</sup> were shown to be independent prognostic factors for ITP remission after LS.



**Table 3.** Univariate logistic regression model for factors potentially affecting remission of immune thrombocytopenic purpura (ITP) after laparoscopic splenectomy (LS).

|  | OR   | 95% CI    | p-Value          |
|--|------|-----------|------------------|
| Male/Female  | 1.23 | 0.61–2.49 | 0.561            |
| Age, with every 1 year   | 0.94 | 0.93–0.97 | <b>&lt;0.001</b> |
| BMI, with every 1 kg/m <sup>2</sup>  | 0.85 | 0.77–0.93 | <b>&lt;0.001</b> |
| LOS, with every 1 day  | 0.82 | 0.59–1.16 | 0.263            |
| Ultrasound length of spleen, with every cm                                 | 1.04 | 0.93–1.16 | 0.522            |
| Lowest preoperative platelet count, with every $1 \times 10^3/\text{mm}^3$ | 1.03 | 0.99–1.07 | 0.080            |
| Preoperative platelet count, with every $1 \times 10^3/\text{mm}^3$        | 1.01 | 1.00–1.01 | <b>0.025</b>     |
| Preoperative steroids administration                                       | 0.35 | 0.04–3.03 | 0.337            |
| Preoperative immunoglobulin administration                                 | 1.11 | 0.50–2.49 | 0.791            |
| Platelet transfusions  | 0.36 | 0.14–0.97 | <b>0.041</b>     |
| Additional spleen  | 1.06 | 0.47–2.37 | 0.889            |
| Perioperative complications  | 1.03 | 0.30–3.56 | 0.952            |
| Blood transfusions   | 0.22 | 0.02–2.57 | 0.223            |
| Operative time, with every 1 min   | 0.99 | 0.98–1.01 | 0.671            |
| Blood loss, with every 1 mL  | 0.99 | 0.98–1.01 | 0.696            |
| Time from diagnosis of ITP to procedures, with every 1 month               | 0.99 | 0.99–1.00 | 0.396            |
| Symptoms   | 0.74 | 0.38–1.45 | 0.376            |
| Preoperative time of conservative treatment, with every 1 month            | 0.99 | 0.98–1.02 | 0.230            |

**Table 4.** Multivariate logistic regression model for factors potentially affecting remission of ITP after LS.

|   | OR   | 95% CI     | p-Value      |
|---|------|------------|--------------|
| Age <41 years   | 4.49 | 1.66–12.09 | <b>0.003</b> |
| BMI < 24.3 kg/m <sup>2</sup>                                  | 4.67 | 1.44–15.16 | <b>0.010</b> |
| Preoperative platelet count $\geq 97 \times 10^3/\text{mm}^3$ | 3.50 | 1.30–9.47  | <b>0.012</b> |
| Platelet transfusions   | 0.75 | 0.21–2.75  | 0.665        |

Additionally, we performed logistic regression for possible risk factors for durable postoperative platelet count  $>50 \times 10^3/\text{mm}^3$ . Table 5 shows the results of univariate logistic regression models. Age, preoperative platelet count, and preoperative platelet transfusions were found to be significant factors in univariate models. ROC analyses were built to set cut-off points for continuous variables. AUC for patient's age was 0.74 (95% CI 0.64–0.84,  $p < 0.001$ ), while for preoperative platelet count it was 0.55 (95% CI 0.41–0.69,  $p = 0.047$ ). Then they were used in multivariate logistic regression, as presented in Table 6. Age <42 years and a preoperative platelet count  $\geq 95 \times 10^3/\text{mm}^3$  were found to independently increase the odds ratio for durable postoperative platelet count above  $50 \times 10^3/\text{mm}^3$ .

**Table 5.** Univariate logistic regression model for factors potentially affecting postoperative platelet count  $>50 \times 10^3/\text{mm}^3$ .

|  | OR   | 95% CI    | p-Value      |
|--|------|-----------|--------------|
| Male/Female  | 1.44 | 0.49–4.23 | 0.505        |
| Age, with every 1 year   | 0.95 | 0.92–0.98 | <b>0.001</b> |
| BMI, with every 1 kg/m <sup>2</sup>  | 0.92 | 0.82–1.03 | 0.131        |
| LOS, with every 1 day  | 1.02 | 0.73–1.45 | 0.889        |
| Ultrasound length of spleen, with every cm                                 | 1.15 | 0.90–1.47 | 0.254        |
| Lowest preoperative platelet count, with every $1 \times 10^3/\text{mm}^3$ | 1.02 | 0.97–1.07 | 0.441        |
| Preoperative platelet count, with every $1 \times 10^3/\text{mm}^3$        | 1.03 | 1.00–1.06 | <b>0.010</b> |
| Preoperative steroids administration                                       | 0.51 | 0.20–1.32 | 0.162        |
| Preoperative immunoglobulin administration                                 | 0.63 | 0.22–1.80 | 0.635        |
| Platelet transfusions  | 0.43 | 0.27–0.71 | <b>0.048</b> |
| Additional spleen  | 1.67 | 0.46–6.11 | 0.435        |
| Perioperative complications  | 2.43 | 0.01–4.65 | 0.981        |
| Blood transfusions   | 0.37 | 0.67–1.69 | 0.695        |
| Operative time, with every 1 min   | 0.99 | 0.97–1.03 | 0.113        |
| Blood loss, with every 1 mL  | 1.00 | 0.99–1.04 | 0.607        |
| Time from diagnosis of ITP to procedures, with every 1 month               | 1.00 | 0.99–1.06 | 0.945        |
| Symptoms   | 0.98 | 0.38–2.55 | 0.966        |
| Preoperative time of conservative treatment, with every 1 month            | 0.99 | 0.98–1.02 | 0.248        |



**Table 6.** Multivariate logistic regression model for factors potentially affecting postoperative PLT  $> 50 \times 10^3/\text{mm}^3$ .

|   | OR   | 95% CI     | p-Value      |
|---|------|------------|--------------|
| Age $< 42$ years  | 4.93 | 1.49–16.34 | <b>0.009</b> |
| Preoperative platelet count $\geq 95 \times 10^3/\text{mm}^3$ | 3.45 | 1.03–11.59 | <b>0.043</b> |
| Platelet transfusions   | 0.69 | 0.23–2.07  | 0.501        |

#### 4. Discussion

In this study we evaluated factors associated with the long-term remission of ITP after LS to help surgeons to identify patients who are expected to benefit from splenectomy. Our study showed that an age  $< 41$  years, a BMI  $< 24.3 \text{ kg/m}^2$  and a preoperative platelet count  $\geq 97 \times 10^3/\text{mm}^3$  are independent factors increasing chance for remission. Regarding durable postoperative platelets at a level of  $> 50 \times 10^3/\text{mm}^3$ , an age  $< 42$  years and a preoperative platelet count  $\geq 95 \times 10^3/\text{mm}^3$  were found to independently increase odds ratios.

Laparoscopic splenectomy is a safe procedure with low mortality and morbidity rates but is not completely free of complications. Asplenic patients are susceptible to opportunistic infections such as life-threatening, overwhelming post-splenectomy infections (OPSI), which is why all patients should receive preoperative vaccines for encapsulated bacteria [18]. According to American Society of Hematologist (ASH) 2011 guidelines, pneumococcal and meningococcal vaccinations for elective splenectomy are recommended and one dose of *H. influenzae* type b vaccine is not contraindicated before splenectomy [19]. A particularly important factor is the increased risk of venous thromboembolic events. In a study by Tastaldi et al. the perioperative morbidity was 7.3%, including three deep vein and two portal vein thromboses, one reoperation for bleeding, and no mortalities [20]. In a study by Thai et al. ITP patients who underwent splenectomy had a 16% venous thromboembolism rate when compared to a 2% rate on a matched cohort that was not treated with surgery [21]. Other studies have shown that the risk for portal or splenic vein thrombosis after splenectomy was estimated to be 0.1–4/100 patient-years [22]. Complications, as described in a work by Rijcken et al. occurred in 6/73 patients (8.2%), which consisted mostly of postoperative bleeding. Five patients (6.8%) required surgery for bleeding control. One patient had an epifascial wound infection after conversion. A limited pleural effusion developed in one patient [6]. In our study, complications occurred in 13 (7.88%) patients. Nine (7.96%) of them occurred in the remission group and four (7.69%) in the non-remission group. There were no conversions. One patient died after surgery due to pulmonary embolism. Although morbidity rates were relatively low, prediction of the efficacy of LS for ITP is still important.

There is no doubt that laparoscopic splenectomy is a valuable and effective treatment of patients with ITP but there are still patients who have a poor long-term response. The present study showed that two-thirds of ITP patients achieved a long-term response after LS during our follow-up periods and one third had no response. In a study by Tastaldi et al. after a median 62-month follow-up, two-thirds (68%) of the patients experienced a sustained response and were treatment-free [20]. Rijcken et al. found stable remission in a total of 44/72 (61.1%) patients [6]. Rui et al. showed that a total of 65 of 78 (83.3%) patients had stable remission and no need for further therapy for ITP after LS [23]. Differences in hematological outcomes might come from different definitions and clinical criteria used in different studies. We defined the response to LS based on recent consensus criteria for complete response (CR) as a platelet count of  $> 100 \times 10^3/\text{mm}^3$  in follow-up [19]. However, it should be noted that studies like Istl et al. defined response to LS as a platelet count greater than  $50 \times 10^3/\text{mm}^3$  with no need for postoperative medical management during the follow-up period [24], so we also performed analyses for that cut-off point. Age and preoperative platelet count remained significant, independent prognostic factors.

Many studies have attempted to indicate conclusive predictive factors of hematological response to splenectomy. Patient age is the most acknowledged predictive factor of successful outcome after splenectomy. The analysis of Duperier et al. revealed that a younger age predicted a successful response to laparoscopic splenectomy specifically in patients younger than 50 years. Conversely, refractory as well as recurrent disease were seen in older patients [25]. Duperier et al. also revealed that an age younger than 50 years had a sensitivity of 72%, a specificity of 68%, a positive predictive value of 58%, and a negative predictive value of 77% [25]. Tastaldi et al. showed that patients who sustained a long-term response were younger ( $44.7 \text{ years} \pm 20.6$  vs.  $53.4 \text{ years} \pm 19.5$ ,  $p = 0.037$ ) [20]. Other investigators Radaelli et al. [26] and Ojima et al. [3] have not found correlation between age and successful response to splenectomy.

Preoperative platelet level has been evaluated as a predictive factor by many researchers. Rijcken et al. reported that patients with a high preoperative platelet count boosted with steroids and immunoglobulins had a stable long-term response [6]. Other studies presented similar results [20,23]. Duperier et al. revealed in a clinical study with a mean follow-up of 22 months that higher preoperative platelet levels predicted a successful response to LS regardless of how this level was achieved [25]. In our study the preoperative platelet count  $\geq 97 \times 10^3/\text{mm}^3$  is a prognostic factor for ITP remission. On the other hand Ojima et al. showed that only a high platelet count on postoperative day seven was associated with a good response to splenectomy [3]. It is worth considering that maybe patients with initially higher platelet levels or those who respond to steroid therapy have less severe ITP. Other factors reported as successful predictors examined by some of investigators are disease duration from diagnosis to splenectomy, and splenic sequestration [27].

Timing of LS is not standardized. Most patients submitted to surgery have already failed in several medical attempts. They probably already have adverse effects such as hypertension, osteoporosis or infections [6]. In our study we observed that duration of ITP did not affect response to surgery. There is however one important factor that has not been studied so far. We believe that conversion from responding to medical treatment to a refractory course may be more important than the duration of the disease. A better outcome is expected in patients who can still achieve a high PLT level responding to medical treatment and do not present adverse effects of medications, which may be optimal timing for LS.

Another interesting aspect of this study was finding that accessory spleens were present in 21.82% patients in general, and this did not differ between groups. This seems not to be a significant clinical finding, yet there were some case reports about recurrent ITP [28,29].

The present study is limited by typical factors for a single-center retrospective analysis. It has a retrospective design. Due to a long period of study duration (19 years) we were not able to precisely analyze hematological preparation for surgery and preoperative conservative treatment. However, the study analyzes remission rates after splenectomy, not preoperative treatment. Indications have not changed over that time, with only patients unsuitable for further conservative treatment operated on. Follow-up is different mostly due to the time interval between the date of surgery and our analysis (follow-up). To collect long-term data, we contacted the patients and checked their remission status. The minimal time interval between surgery and follow-up was one year after surgery. Additionally, some patients were lost to follow up and we did not include them in the analysis. However, the study group is still relatively large and permitted the drawing of reliable results and conclusions. Moreover, patients were operated on by several surgeons with different levels of experience. Another limitation was that we did not include potential postoperative complications that might have occurred later than 30 days after discharge in this analysis. Those complications may have influenced the overall complication rate.

## 5. Conclusions

Laparoscopic splenectomy is a safe and effective treatment of pharmacologically refractory ITP. The majority of patients achieved long-term responses in this study. Independent prognostic factors for



ITP remission after LS revealed in our study are: age <41 years, BMI < 24.3 kg/m<sup>2</sup>, and preoperative platelet count  $\geq 97 \times 10^3/\text{mm}^3$ . Duration of ITP and treatment time were unrelated to remission after LS. Further studies are necessary to assess patient-related predictive factors of response to surgical therapy for determination of optimal approach and optimal surgical timing.

**Author Contributions:** Conceptualization, A.K. and D.R.; methodology, A.K. and M.W.; data obtaining, G.T., N.G., A.L.; formal Analysis, M.W. and J.K.; data curation, M.W., and G.T.; writing—original draft preparation, A.K., J.K., A.B.; writing—review and editing, D.R., A.B. and M.P.; supervision, A.B. and M.P.

**Funding:** This study received no funding.

**Conflicts of Interest:** Authors declare no conflict of interest.

## References

1. Akwari, O.E.; Itani, K.M.F.; Coleman, R.E.; Rosse, W.F. Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). *Ann. Surg.* **1987**, *206*, 529–541. [[CrossRef](#)]
2. George, J.N.; Woolf, S.H.; Raskob, G.E.; Wasser, J.S.; Aledort, L.M.; Ballem, P.J.; Blanchette, V.S.; Bussel, J.B.; Cines, D.B.; Kelton, J.G.; et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. *Blood* **1996**, *88*, 3–40. [[CrossRef](#)] [[PubMed](#)]
3. Ojima, H.; Kato, T.; Araki, K.; Okamura, K.; Manda, R.; Hirayama, I.; Hosouchi, Y.; Nishida, Y.; Kuwano, H. Factors predicting long-term responses to splenectomy in patients with idiopathic thrombocytopenic purpura. *World J. Surg.* **2006**, *30*, 553–559. [[CrossRef](#)] [[PubMed](#)]
4. Kang, C.M.; Lee, J.G.; Kim, K.S.; Choi, J.S.; Lee, W.J.; Kim, B.R.; Ko, Y.W.; Han, J.S.; Min, Y.H. Long-term follow-up of laparoscopic splenectomy in patients with immune thrombocytopenic purpura. *J. Korean Med. Sci.* **2007**, *22*, 420–424. [[CrossRef](#)] [[PubMed](#)]
5. Delaitre, B.; Maignien, B. Splenectomy by the laparoscopic approach. Report of a case. *Presse Med.* **1991**, *20*, 2263. [[PubMed](#)]
6. Rijcken, E.; Mees, S.T.; Bispin, G.; Krueger, K.; Bruewer, M.; Senninger, N.; Mennigen, R. Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP): A retrospective cohort study on longtime response predicting factors based on consensus criteria. *Int. J. Surg.* **2014**, *12*, 1428–1433. [[CrossRef](#)]
7. Delaitre, B.; Blezel, E.; Samama, G.; Barrat, C.; Gossot, D.; Bresler, L.; Meyer, C.; Heyd, B.; Collet, D.; Champault, G.; et al. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura. *Surg. Laparosc. Endosc. Percutan. Tech.* **2002**, *12*, 412–419. [[CrossRef](#)] [[PubMed](#)]
8. Winslow, E.R.; Brunt, L.M. Perioperative outcomes of laparoscopic versus open splenectomy: A meta-analysis with an emphasis on complications. *Surgery* **2003**, *134*, 647–653. [[CrossRef](#)]
9. Pattenden, C.J.; Mann, C.D.; Metcalfe, M.S.; Dyer, M.; Lloyd, D.M. Laparoscopic splenectomy: A personal series of 140 consecutive cases. *Ann. R. Coll. Surg. Engl.* **2010**, *92*, 398–402. [[CrossRef](#)]
10. Zychowicz, A.; Radkowiak, D.; Lasek, A.; Małczak, P.; Witowski, J.; Major, P.; Strzałka, M.; Kulawik, J.; Budzyński, A.; Pędziwiatr, M.; et al. The safety of laparoscopic splenectomy for immune thrombocytopenia in patients with very low platelet count. *Videosurgery Other Miniinvasive Tech.* **2018**, *13*, 157–163. [[CrossRef](#)]
11. Gutierrez, G.; Reines, H.D.; Wulf-Gutierrez, M.E. Clinical review: Hemorrhagic shock. *Crit. Care* **2004**, *8*, 373–381. [[CrossRef](#)]
12. Kathariya, R.; Devanoorkar, A.; Jain, H. Intra-Operative Hemorrhage: A Review of Literature. *J. Med. Diagn. Methods* **2013**, *2*, 1–5. [[CrossRef](#)]
13. Dindo, D.; Demartines, N.; Clavien, P.A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann. Surg.* **2004**, *240*, 205–213. [[CrossRef](#)] [[PubMed](#)]
14. Major, P.; Matlok, M.; Pędziwiatr, M.; Budzyński, A. Do we really need routine drainage after laparoscopic adrenalectomy and splenectomy? *Videosurgery Other Miniinvasive Tech.* **2012**, *7*, 33–39. [[CrossRef](#)]
15. Radkowiak, D.; Zychowicz, A.; Lasek, A.; Wysocki, M.; Major, P.; Pędziwiatr, M.; Budzyński, P.; Kulawik, J.; Budzyński, A. 20 years' experience with laparoscopic splenectomy. Single center outcomes of a cohort study of 500 cases. *Int. J. Surg.* **2018**, *52*, 285–292. [[CrossRef](#)]

16. Radkowiak, D.; Zychowicz, A.; Wysocki, M.; Lasek, A.; Major, P.; Pędziwiatr, M.; Budzyński, P.; Dembiński, M.; Dworak, J.; Budzynski, A.; et al. Quest for the optimal technique of laparoscopic splenectomy—Vessels first or hilar transection? *Videosurgery Other Miniinvasive Tech.* **2018**, *13*, 460. [\[CrossRef\]](#)
17. Motheral, B.; Brooks, J.; Clark, M.A.; Crown, W.H.; Davey, P.; Hutchins, D.; Martin, B.C.; Stang, P.A. A checklist for retrospective database studies—Report of the ISPOR task force on retrospective databases. *Value Health* **2003**, *6*, 90–97. [\[CrossRef\]](#)
18. Yeh, C.C.; Liao, C.C.; Chang, Y.C.; Jeng, L.B.; Yang, H.R.; Shih, C.C.; Chen, T.L. Adverse outcomes after noncardiac surgery in patients with diabetes: A nationwide population-based retrospective cohort study. *Diabetes Care* **2013**, *36*, 3216–3221. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Neunert, C.; Lim, W.; Crowther, M.; Cohen, A.; Solberg, L.; Crowther, M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood* **2011**, *117*, 4190–4207. [\[CrossRef\]](#)
20. Tastaldi, L.; Krpata, D.M.; Prabhu, A.S.; Petro, C.C.; Haskins, I.N.; Perez, A.J.; Alkhatib, H.; Colturato, I.; Tu, C.; Lichtin, A.; et al. Laparoscopic splenectomy for immune thrombocytopenia (ITP): Long-term outcomes of a modern cohort. *Surg. Endosc. Other Interv. Tech.* **2019**, *33*, 475–485. [\[CrossRef\]](#)
21. Thai, L.H.; Mahévas, M.; Roudot-Thoraval, F.; Limal, N.; Languille, L.; Dumas, G.; Khellaf, M.; Bierling, P.; Michel, M.; Godeau, B.; et al. Long-term complications of splenectomy in adult immune thrombocytopenia. *Medicine* **2016**, *95*, e5098. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Cuker, A.; Cines, D.B.; Neunert, C.E. Controversies in the treatment of immune thrombocytopenia. *Curr. Opin. Hematol.* **2016**, *23*, 479–485. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Liao, R.; Tang, P.-Y.; Song, J.-F.; Qin, K.-L.; Wang, X.; Yan, X. Platelet count on preoperative day 1 predicts the long-term responses to laparoscopic splenectomy for Chinese patients with medically refractory idiopathic thrombocytopenic purpura. *BMC Surg.* **2018**, *18*, 108. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Istl, A.C.; McCreery, G.; Allen, L.J.; Vogt, K.; Dubois, L.; Gray, D.K. Corticosteroid response predicts success of laparoscopic splenectomy in treating immune thrombocytopenia. *Surgery* **2018**, *164*, 71–76. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Duperier, T.; Brody, F.; Felsher, J.; Walsh, R.M.; Rosen, M.; Ponsky, J. Predictive Factors for Successful Laparoscopic Splenectomy in Patients with Immune Thrombocytopenic Purpura. *Arch. Surg.* **2004**, *139*, 61–66. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Radaelli, F.; Faccini, P.; Goldaniga, M.; Guggiari, E.; Pozzoli, E.; Maiolo, A.T.; Ciani, A.; Pogliani, E.M. Factors predicting response to splenectomy in adult patients with idiopathic thrombocytopenic purpura. *Haematologica* **2000**, *85*, 1040–1044. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Zheng, D.; Huang, C.-S.; Huang, S.-B.; Zheng, C.-X. Laparoscopic splenectomy for primary immune thrombocytopenia: Current status and challenges. *World J. Gastrointest. Endosc.* **2016**, *8*, 610–615. [\[CrossRef\]](#)
28. Woo, J.H.; Park, S.H.; Park, Y.K.; Choi, C.B.; Choi, Y.Y.; Myung, J.A.; Kim, I.S. Postsplenectomy recurrence of thrombocytopenia with an accessory spleen. *Korean J. Intern. Med.* **2004**, *19*, 199–201. [\[CrossRef\]](#) [\[PubMed\]](#)
29. Choi, Y.U.; Dominguez, E.P.; Sherman, V.; Sweeney, J.F. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. *JSLS* **2008**, *12*, 314–317. [\[PubMed\]](#)

